Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)

Paul M Ridker, Jean G MacFadyen, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Børge Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn, JUPITER Study Group, Paul M Ridker, Jean G MacFadyen, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P KasteleinWolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Børge G Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn, JUPITER Study Group

    108 Citationer (Scopus)

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)'. Sammen danner de et unikt fingeraftryk.

    Medicin og biovidenskab